Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609808 | 0.91 | SMN1; SMN2 (0.82) | SMN1; SMN2POLBHPGDMAPTALDH1A1 | |
| SCHEMBL13647687 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2TDP1POLBHPGDMAPT | |
| SCHEMBL12444551 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2TDP1HPGDMAPTALDH1A1 | |
| SCHEMBL12444549 | 0.84 | ALDH1A1 (0.55) | SMN1; SMN2TDP1HPGDMAPTALDH1A1 | |
| Urethane SCHEMBL10734046 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBHPGDMAPTALDH1A1 | |
| SCHEMBL7251623 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2POLBHPGDMAPTALDH1A1 | |
| SCHEMBL13186583 | 0.83 | LMNA (0.78) | SMN1; SMN2POLBHPGDMAPTALDH1A1 | |
| SCHEMBL6790845 | 0.83 | TDP1 (0.57) | SMN1; SMN2TDP1POLBMAPTALDH1A1 | |
| SCHEMBL514570 | 0.83 | TDP1 (0.57) | SMN1; SMN2TDP1POLBMAPTALDH1A1 | |
| SCHEMBL18814226 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TDP1POLBHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462429-A | Method for synthesizing amino-methyl-phenyl methyl carbamate compound from p-toluidine | 河北工业大学 | 2025-02-18 | — | — | CN | claimed |
| CN-103562198-B | There is muscarinic receptor antagonist and the compound of beta 2-adrenergic receptor agonists activity | 奇斯药制品公司 | 2016-08-24 | — | — | CN | claimed |
| CN-103562198-A | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMA SPA | 2014-02-05 | — | — | CN | claimed |
| US-20250188021-A1 | PREPARATION METHOD FOR ALICYCLIC CARBAMATE AND USE THEREOF | INSTITUTE OF PROCESS ENGINEERING, CHINESE ACADEMY OF SCIENCES (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-119462429-A | Method for synthesizing amino-methyl-phenyl methyl carbamate compound from p-toluidine | 河北工业大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-117362188-A | Synthesis method of alpha-substituted deuterated amino acid ester | 广州医科大学 | 2024-01-09 | — | — | CN | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3628044-B1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2023168889-A1 | PREPARATION METHOD FOR ALICYCLIC CARBAMATE AND USE THEREOF | 中国科学院过程工程研究所 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023168889-A1 | PREPARATION METHOD FOR ALICYCLIC CARBAMATE AND USE THEREOF | 中国科学院过程工程研究所 | 2023-09-14 | — | — | WO | disclosed |
| US-4603216-A | RUTHENIUM-PHOSPHINE CATALYST | CATALYTICA ASSOCIATES (US) | 1986-07-29 | — | — | US | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| US-4600793-A | Process for the preparation of urethanes | CATALYTICA ASSOCIATES (US) | 1986-07-15 | — | — | US | disclosed |
| EP-0157828-A1 | PROCESS FOR THE PREPARATION OF URETHANES. | CATALYTICA ASSOCIATES (US) | 1985-10-16 | — | — | EP | disclosed |
| WO-1985001285-A1 | PROCESS FOR THE PREPARATION OF URETHANES | CATALYTICA ASSOCIATES (US) | 1985-03-28 | — | — | WO | disclosed |
| US-4487713-A | HEAT TREATMENT WITH TITANIUM, TIN, ANTIMONY OR ZIRCONIUM COMPOUND | EXXON RESEARCH & ENGINEERING CO. (US) | 1984-12-11 | — | — | US | disclosed |
| US-4081472-A | CATALYTIC, FROM A CARBAMATE | MITSUI TOATSU CHEMICALS INC. (JA) | 1978-03-28 | — | — | US | disclosed |
| US-4069240-A | GROUP 8 METAL CATALYST | UNIROYAL, INC. (US) | 1978-01-17 | — | — | US | disclosed |
| US-3962302-A | Production of isocyanates from esters of carbamic acids (urethanes) | ATLANTIC RICHFIELD COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188021-A1 | PREPARATION METHOD FOR ALICYCLIC CARBAMATE AND USE THEREOF | PAICS, CPS1, JMJD6 | SMN1; SMN2 3727/4885TDP1 2180/4885POLB 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.